Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Payables: 2010-2025

Historic Payables for Catalyst Pharmaceuticals (CPRX) over the last 13 years, with Sep 2025 value amounting to $9.1 million.

  • Catalyst Pharmaceuticals' Payables fell 21.34% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.4 million, marking a year-over-year decrease of 3.02%. This contributed to the annual value of $16.6 million for FY2024, which is 12.15% up from last year.
  • As of Q3 2025, Catalyst Pharmaceuticals' Payables stood at $9.1 million, which was up 64.54% from $5.5 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Payables registered a high of $16.6 million during Q4 2024, and its lowest value of $2.3 million during Q2 2022.
  • Over the past 3 years, Catalyst Pharmaceuticals' median Payables value was $9.1 million (recorded in 2025), while the average stood at $9.0 million.
  • Per our database at Business Quant, Catalyst Pharmaceuticals' Payables slumped by 49.63% in 2021 and then surged by 272.20% in 2023.
  • Catalyst Pharmaceuticals' Payables (Quarterly) stood at $2.8 million in 2021, then surged by 43.61% to $4.0 million in 2022, then skyrocketed by 272.20% to $14.8 million in 2023, then increased by 12.15% to $16.6 million in 2024, then declined by 21.34% to $9.1 million in 2025.
  • Its last three reported values are $9.1 million in Q3 2025, $5.5 million for Q2 2025, and $11.2 million during Q1 2025.